Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 5/2012

01-10-2012 | Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Evolving Concepts of Oxidative Stress and Reactive Oxygen Species in Cardiovascular Disease

Authors: Kai Chen, John F. Keaney Jr.

Published in: Current Atherosclerosis Reports | Issue 5/2012

Login to get access

Abstract

Cardiovascular disease (CVD) continues to be a substantial health-care burden, despite recent treatment advances. Oxidative stress has long been regarded as a key pathophysiological mediator that ultimately leads to CVD including atherosclerosis, hypertension and heart failure. Over the past decade, emerging evidence has shifted our understanding of reactive oxygen species (ROS) from its harmful role to being signaling molecules. Here, we reviewed recent advances in our understanding of ROS that mediate the complex process of CVDs, with a focus on major ROS signaling and sources such as mitochondria and Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidases.
Literature
1.
Keaney JF, Larson MG, Vasan RS, Wilson PWF, Lipinska I, Corey D, et al. Framingham Study. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23:434–39.PubMedCrossRef
2.
Rao F, Zhang K, Khandrika S, Mahata M, Fung MM, Ziegler MG, et al. Isoprostane, an “intermediate phenotype” for oxidative stress heritability, risk trait associations, and the influence of chromogranin B polymorphism. J Am Coll Cardiol. 2010;56:1338–50.PubMedCrossRef
3.
4.
Kuijpers T, Lutter R. Inflammation and repeated infections in CGD: two sides of a coin. Cell Mol Life Sci. 2012;69:7–15.PubMedCrossRef
5.
West AP, Brodsky IE, Rahner C, Woo DK, Erdjument-Bromage H, Tempst P, et al. TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature. 2011;472:476–80.PubMedCrossRef
6.
Urao N, Inomata H, Razvi M, Kim HW, Wary K, McKinney R, et al. Role of nox2-based NADPH oxidase in bone marrow and progenitor cell function involved in neovascularization induced by hindlimb ischemia. Circ Res. 2008;103:212–20.PubMedCrossRef
7.
• Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, Horowitz JC, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med. 2009;15:1077–81. This article shows that TGF-beta-1-induced Nox4 expression and genetic or pharmacologic targeting of Nox4 abrogates fibrogenesis in lung injury mice models.PubMedCrossRef
8.
Chen C, Thomas SR, Keaney JF. Beyond LDL oxidation: ROS in vascular signal transduction. Free Radic Biol Med. 2003;35:117–32.PubMedCrossRef
9.
Liu X, Zweier JL. A real-time electrochemical technique for measurement of cellular hydrogen peroxide generation and consumption: evaluation in human polymorphonuclear leukocytes. Free Radic Biol Med. 2001;31:894–901.PubMedCrossRef
10.
Storozhevykh TP, Senilova YE, Persiyantseva NA, Pinelis VG, Pomytkin IA. Mitochondrial respiratory chain is involved in insulin-stimulated hydrogen peroxide production and plays an integral role in insulin receptor autophosphorylation in neurons. BMC Neurosci. 2007;8:84.PubMedCrossRef
11.
Jin H, Heller DA, Kalbacova M, Kim J-H, Zhang J, Boghossian AA, et al. Detection of single-molecule H2O2 signalling from epidermal growth factor receptor using fluorescent single-walled carbon nanotubes. Nat Nanotechnol. 2010;5:302–9.PubMedCrossRef
12.
D’Autréaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8:813–24.PubMedCrossRef
13.
Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381–478.PubMedCrossRef
14.
15.
Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal. 2010;13:39–75.PubMedCrossRef
16.
Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, et al. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation. 1999;100:1494–8.PubMedCrossRef
17.
Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002;105:1429–35.PubMedCrossRef
18.
Judkins CP, Diep H, Broughton BRS, Mast AE, Hooker EU, Miller AA, et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol. 2010;298:H24–32.PubMedCrossRef
19.
Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol. 2008;52:1803–9.PubMedCrossRef
20.
Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res. 1992;275:169–80.PubMedCrossRef
21.
Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221–5.PubMedCrossRef
22.
Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61.PubMedCrossRef
23.
Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20:1262–75.PubMedCrossRef
24.
• Liao X, Sluimer JC, Wang Y, Subramanian M, Brown K, Pattison JS, et al. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab. 2012;15:545–53. This article showed that inhibition of autophagy promotes apoptosis and NADPH oxidase-mediated oxidative stress, and defective efferocytosis.PubMedCrossRef
25.
Epstein BJ, Smith SM, Choksi R. Recent changes in the landscape of combination RAS blockade. Expert Rev Cardiovasc Ther. 2009;7:1373–84.PubMedCrossRef
26.
Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol. 2003;285:R117–24.PubMed
27.
Kitiyakara C, Chabrashvili T, Chen Y, Blau J, Karber A, Aslam S, et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol. 2003;14:2775–82.PubMedCrossRef
28.
• Feng D, Yang C, Geurts AM, Kurth T, Liang M, Lazar J, et al. Increased expression of NAD(P)H oxidase subunit p67(phox) in the renal medulla contributes to excess oxidative stress and salt-sensitive hypertension. Cell Metab. 2012;15:201–8. This article shows that the higher expression of p67(phox), not the other subunits, was associated with higher Nox activity and salt sensitivity, and disruption of p67(phox) resulted in reduction of salt-sensitive hypertension and renal medullary oxidative stress/injury.PubMedCrossRef
29.
Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation. 2005;112:2677–85.PubMedCrossRef
30.
Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001;88:947–53.PubMedCrossRef
31.
Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–60.PubMedCrossRef
32.
Zhang A, Jia Z, Wang N, Tidwell TJ, Yang T. Relative contributions of mitochondria and NADPH oxidase to deoxycorticosterone acetate-salt hypertension in mice. Kidney Int. 2011;80:51–60.PubMedCrossRef
33.
• Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, et al. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res. 2010;107:106–16. This article shows that treatment with the mitochondrial-targeted antioxidant mitoTEMPO attenuated hypertension and overexpression of SOD2 in transgenic mice demonstreated attenuated angiotensin-II-induced hypertension.PubMedCrossRef
34.
Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, Ertl G, et al. Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension. 2009;54:338–44.PubMedCrossRef
35.
Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488–96.PubMedCrossRef
36.
37.
Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002;91:1160–7.PubMedCrossRef
38.
Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation. 2005;111:2347–55.PubMedCrossRef
39.
Bhandarkar SS, Jaconi M, Fried LE, Bonner MY, Lefkove B, Govindarajan B, et al. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest. 2009;119:2359–65.PubMed
40.
•• Craige SM, Chen C, Pei Y, Li C, Huang X, Chen C, et al. NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation. 2011;124:731–40. This article shows endothelial-specific Nox4-overexpressing mice had accelerated recovery from hindlimb ischemia through enhanced angiogenesis.PubMedCrossRef
41.
•• Schröder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, et al. Nox4 Is a Protective Reactive Oxygen Species Generating Vascular NADPH Oxidase. Circ Res. 2012 in press. This article shows that Nox4-null mice exhibited attenuated angiogenesis and reduced eNOS expression.
42.
Thomas SR, Chen C, Keaney JF. Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway. J Biol Chem. 2002;277:6017–24.PubMedCrossRef
43.
Hartvigsen K, Chou M-Y, Hansen LF, Shaw PX, Tsimikas S, Binder CJ, et al. The role of innate immunity in atherogenesis. J Lipid Res. 2009;50(Suppl):S388–93.PubMedCrossRef
44.
Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46–57.PubMedCrossRef
45.
Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788–95.PubMedCrossRef
46.
• Briley-Saebo KC, Cho Y-S, Shaw PX, Ryu SK, Mani V, Dickson S, et al. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J Am Coll Cardiol. 2011;57:337–47. This article shows following intravenous injection of targeted Mn micelles, strong MR signal was observed 48–72 h with colocalization within intraplaque macrophages.PubMedCrossRef
47.
Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57–63.PubMedCrossRef
48.
Vita JA, Brennan M-L, Gokce N, Mann SA, Goormastic M, Shishehbor MH, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134–9.PubMedCrossRef
49.
Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, CAPTURE Investigators, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–5.PubMedCrossRef
50.
Nicholls SJ, Tang WHW, Brennan D, Brennan M-L, Mann S, Nissen SE, et al. Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem. 2011;57:1762–70.PubMedCrossRef
51.
Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest. 1996;97:1535–44.PubMedCrossRef
52.
Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879–91.PubMedCrossRef
53.
Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894–900.PubMedCrossRef
54.
Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5–12.PubMedCrossRef
55.
Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006;113:1871–8.PubMedCrossRef
56.
Shih J, Datwyler SA, Hsu SC, Matias MS, Pacenti DP, Lueders C, et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem. 2008;54:1076–9.PubMedCrossRef
57.
Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. The HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Vit E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154–60.PubMedCrossRef
58.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33.CrossRef
59.
Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al. HOPE and HOPE-TOO Trial Investigators. Effect of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized, controlled trial. JAMA. 2005;293:1338–47.PubMedCrossRef
60.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, JUPITER Trial Study Group, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–82.PubMedCrossRef
61.
Singh U, Devaraj S, Jialal I, Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol. 2008;102:321–5.PubMedCrossRef
62.
Wang C-Y, Liu P-Y, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14:37–44.PubMedCrossRef
63.
• Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang M-H, Tousoulis D, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation. 2011;124:335–45. This article shows statin treatment in patients undergoing coronary artery bypass graft surgery was associated with improved vascular nitric oxide bioavailability and reduced superoxide generation in internal mammary artery.PubMedCrossRef
64.
Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RAJ, Murphy MP, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 2005;19:1088–95.PubMedCrossRef
65.
•• Mercer JR, Yu E, Figg N, Cheng K-K, Prime TA, Griffin JL, et al. The mitochondria-targeted antioxidant MitoQ decreases features of the metabolic syndrome in ATM+/-/ApoE-/- mice. Free Radic Biol Med. 2012;52:841–9. This article shows that MitoQ intake orally prevented the increased adposity, hypercholesterolemia, and hypertriglyceridemia, and corrected hyperglycemia and hepatic steatosis.PubMedCrossRef
66.
• Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, et al. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30:1019–26. This article shows that treatment with oral MitoQ in patients with hepatitis C decreased alanine transaminase and aspartate aminotransferase levels without changes in viral load.PubMedCrossRef
67.
Smith RAJ, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci. 2010;1201:96–103.PubMedCrossRef
68.
Albrecht SC, Barata AG, Grosshans J, Teleman AA, Dick TP. In vivo mapping of hydrogen peroxide and oxidized glutathione reveals chemical and regional specificity of redox homeostasis. Cell Metab. 2011;14:819–29.PubMedCrossRef
69.
70.
Zhang L, Nguyen MVC, Lardy B, Jesaitis AJ, Grichine A, Rousset F, et al. New insight into the Nox4 subcellular localization in HEK293 cells: first monoclonal antibodies against Nox4. Biochimie. 2011;93:457–68.PubMedCrossRef
Metadata
Title
Evolving Concepts of Oxidative Stress and Reactive Oxygen Species in Cardiovascular Disease
Authors
Kai Chen
John F. Keaney Jr.
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 5/2012
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-012-0266-8

Other articles of this Issue 5/2012

Current Atherosclerosis Reports 5/2012 Go to the issue

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Glucagon-Like Peptide-1 and its Cardiovascular Effects

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Discovery, Translation, and Clinical Investigation

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Novel Immune Signals and Atherosclerosis

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Molecular Imaging in Atherosclerosis: FDG PET

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Making a Difference: Monocyte Heterogeneity in Cardiovascular Disease

Clinical Trials and Their Interpretations (J Plutzky, Section Editor)

Regulation of Atherosclerosis and Associated Risk Factors by Adenosine and Adenosine Receptors

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits